Cargando…

The Shuganhuazheng Formula in Triple-Negative Breast Cancer: A Study Based on Network Pharmacology and In Vivo Experiments

Breast cancer is the most common cancer in women. Among breast cancer subtypes, triple-negative breast cancer (TNBC) has the highest degree of malignancy and the worst prognosis. The Shuganhuazheng formula (SGHZF) is a traditional Chinese herbal formula for the treatment of TNBC, but the mechanism o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Bo, Fei, Rui, Yang, Yan, Jing, Niancai, Lu, Yi, Xiao, Hongyu, Yang, Jili, Zhang, Yue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752265/ https://www.ncbi.nlm.nih.gov/pubmed/33414839 http://dx.doi.org/10.1155/2020/8173147

Ejemplares similares

Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo
por: Park, See-Hyoung, et al.
Publicado: (2016)

Traditional Chinese Medicine Syndromes are Associated with Driver Gene Mutations and Clinical Characteristics in Patients with Lung Adenocarcinoma
por: Yang, Jili, et al.
Publicado: (2022)

Yiqi Formula Enhances the Antitumor Effects of Erlotinib for Treatment of Triple-Negative Breast Cancer Xenografts
por: Liao, Ming-juan, et al.
Publicado: (2014)

Identifying the Effect of Ursolic Acid Against Triple-Negative Breast Cancer: Coupling Network Pharmacology With Experiments Verification
por: Zhang, Yubao, et al.
Publicado: (2021)

Molecular mechanism of Ruxian Shuhou prescription in the treatment of triple-negative breast cancer based on network pharmacology
por: Chu, Meiling, et al.
Publicado: (2023)

Exploring the mechanism of an active ingredient of ginger, dihydrocapsaicin, on triple negative breast cancer based on network pharmacology and in vitro experiments
por: Luo, Liming, et al.
Publicado: (2023)

Network Pharmacology–Based Identification of Key Mechanisms of Xihuang Pill in the Treatment of Triple-Negative Breast Cancer Stem Cells
por: Zhang, Yu-Zhu, et al.
Publicado: (2021)

Identification of Target Genes Related to Sulfasalazine in Triple-Negative Breast Cancer Through Network Pharmacology
por: Yu, Haochen, et al.
Publicado: (2020)

Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer
por: Tang, Jing, et al.
Publicado: (2019)

Suppression of Invasion and Metastasis of Triple-Negative Breast Cancer Lines by Pharmacological or Genetic Inhibition of Slug Activity()()()
por: Ferrari-Amorotti, Giovanna, et al.
Publicado: (2014)

Network Pharmacology and Experimental Validation to Explore the Effect and Mechanism of Kanglaite Injection Against Triple-Negative Breast Cancer
por: Zhao, Mei, et al.
Publicado: (2023)

Frontier progress of the combination of modern medicine and traditional Chinese medicine in the treatment of hepatocellular carcinoma
por: Wei, Lai, et al.
Publicado: (2022)

Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis
por: Lin, Ying-Yi, et al.
Publicado: (2022)

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer
por: Iskit, Sedef, et al.
Publicado: (2016)

Optimizing the Pharmacological Properties of Discoidal Polymeric Nanoconstructs Against Triple-Negative Breast Cancer Cells
por: Ferreira, Miguel, et al.
Publicado: (2020)

The Modulatory Properties of Astragalus membranaceus Treatment on Triple-Negative Breast Cancer: An Integrated Pharmacological Method
por: Liu, Cun, et al.
Publicado: (2019)

c‐Src inhibitor selectively inhibits triple‐negative breast cancer overexpressed Vimentin in vitro and in vivo
por: Lou, Longquan, et al.
Publicado: (2018)

In vitro antineoplastic activity in triple-negative breast cancer cell line and in vivo
por: Madeira, Klesia, et al.
Publicado: (2014)

Methionine deprivation suppresses triple-negative breast cancer metastasis in vitro and in vivo
por: Jeon, Hyein, et al.
Publicado: (2016)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

Unraveling the Pivotal Network of Ultrasound and Somatic Mutations in Triple-Negative and Non-Triple-Negative Breast Cancer
por: Huang, Yunxia, et al.
Publicado: (2023)

Aquaporin 1 knockdown inhibits triple-negative breast cancer cell proliferation and invasion in vitro and in vivo
por: Ji, Yinan, et al.
Publicado: (2021)

Effectiveness of the Sanyin Formula Plus Chemotherapy on Survival in Women With Triple-Negative Breast Cancer: A Randomized Controlled Trial
por: Wu, Chunyu, et al.
Publicado: (2022)

Combination of Chinese medicinal formulas and chemotherapy for triple-negative breast cancer strengthens body resistance to eliminate pathogenic factors
por: Zhang, Yiyi, et al.
Publicado: (2022)

Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Systems Medicine Design for Triple-Negative Breast Cancer and Non-Triple-Negative Breast Cancer Based on Systems Identification and Carcinogenic Mechanisms
por: Yeh, Shan-Ju, et al.
Publicado: (2021)

Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor
por: Han, Rui, et al.
Publicado: (2022)

Exploring the molecular targets and mechanisms of [10]-Gingerol for treating triple-negative breast cancer using bioinformatics approaches, molecular docking, and in vivo experiments
por: Huang, Ping, et al.
Publicado: (2021)

Rewiring of the Endocrine Network in Triple-Negative Breast Cancer
por: Li, Kaixuan, et al.
Publicado: (2022)

Clinicopathologic features of triple negative breast cancers: an experience from Pakistan
por: Hashmi, Atif Ali, et al.
Publicado: (2014)

Pharmacological induction of cell surface GRP78 contributes to apoptosis in triple negative breast cancer cells
por: Raiter, Annat, et al.
Publicado: (2014)

Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer
por: Singleton, Dean C., et al.
Publicado: (2020)

Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer
por: Powell, Reid T., et al.
Publicado: (2020)

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
por: Wang, Hanwen, et al.
Publicado: (2021)

Comprehensive Analysis of the Implication of PGRMC1 in Triple-Negative Breast Cancer
por: Xu, Xin, et al.
Publicado: (2021)

In vivo CRISPR screens identify RhoV as a pro‐metastasis factor of triple‐negative breast cancer
por: Jin, Ming‐Liang, et al.
Publicado: (2023)

Deciphering the Pharmacological Mechanisms of the Huayu-Qiangshen-Tongbi Formula Through Integrating Network Pharmacology and In Vitro Pharmacological Investigation
por: Wang, Zihao, et al.
Publicado: (2019)

Network pharmacology and in vivo experiment-based strategy to investigate mechanisms of JingFangFuZiLiZhong formula for ulcerative colitis
por: Wang, Mengyuan, et al.
Publicado: (2022)

Mechanism of Xiezhuo Huayu Yiqi Tongluo Formula in the Treatment of Uric Acid Nephropathy Based on Network Pharmacology, Molecular Docking, and In Vivo Experiments
por: Fan, Lifei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5jprb1f5n9nrumbt3u87t1v6h3